Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118035 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL5122115 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL14012890 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL5122959 | 0.82 | HTR2C (0.45) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL14609981 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL26113894 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL204641 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AHTR2CALDH1A1 | |
| SCHEMBL253427 | 0.79 | HTR2C (0.48) | SMN1; SMN2NPC1RAB9AHTR2CALDH1A1 | |
| SCHEMBL26115372 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL5127061 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| EP-3533797-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-2540728-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20170209452-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-9655900-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20160310494-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9388195-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20150158882-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8933069-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8921354-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140235615-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140228352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8722660-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-2540728-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310494-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | SMN1; SMN2 2614/4885NPC1 792/4885RAB9A 1954/4885 |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | SMN1; SMN2 1318/4885NPC1 2716/4885RAB9A 3649/4885 |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | SMN1; SMN2 2614/4885NPC1 792/4885RAB9A 1954/4885 |
| US-20150158882-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | SMN1; SMN2 2614/4885NPC1 792/4885RAB9A 1954/4885 |
| US-20140228352-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | SMN1; SMN2 2614/4885NPC1 792/4885RAB9A 1954/4885 |
| US-20140235615-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | SMN1; SMN2 2614/4885NPC1 792/4885RAB9A 1954/4885 |
| US-20170209452-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | SMN1; SMN2 2614/4885NPC1 792/4885RAB9A 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.